Health Canada Agrees to Reconsider Tesamorelin

Nov 01, 2013
PDF Version
Supporting Materials:

Theratechnologies Inc. (TSX: TH) today announced that Health Canada has agreed to resume review of the tesamorelin New Drug Submission (NDS) and has rescinded the notice of non-compliance/withdrawal (NON/w) it issued in March 2013.